Genetic predictors for FVIII inhibitors formation in a Greek population of children with severe haemophilia A exclusively treated with recombinant concentrates

Documenti analoghi

• Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis
  di: Konstantina Bolou, et al.
  Pubblicazione: (2025)
• Circulating and Synovial Fluid Levels of YKL‐40 Protein in Patients With Severe Haemophilia A: Preliminary Observations
  di: Aikaterini Michalopoulou, et al.
  Pubblicazione: (2026)
• Muscle Strength in Children and Adolescents With Haemophilia on Prophylaxis: An Age‐Adjusted Dynamometric Study
  di: Dimitrios Syrengelas, et al.
  Pubblicazione: (2026)
• Haemophilia Infants Gross Motor Development: Comparisons With Full‐Term and Preterm Infants of the Same Nationality
  di: Dimitrios Syrengelas, et al.
  Pubblicazione: (2025)
• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)